These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 17982079)

  • 1. Targeting IFN-alpha to B cell lymphoma by a tumor-specific antibody elicits potent antitumor activities.
    Huang TH; Chintalacharuvu KR; Morrison SL
    J Immunol; 2007 Nov; 179(10):6881-8. PubMed ID: 17982079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity.
    Dela Cruz JS; Trinh KR; Morrison SL; Penichet ML
    J Immunol; 2000 Nov; 165(9):5112-21. PubMed ID: 11046042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A murine B cell lymphoma expressing human HER2 / neu undergoes spontaneous tumor regression and elicits antitumor immunity.
    Penichet ML; Dela Cruz JS; Challita-Eid PM; Rosenblatt JD; Morrison SL
    Cancer Immunol Immunother; 2001 Feb; 49(12):649-62. PubMed ID: 11258791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delivery of NKG2D ligand using an anti-HER2 antibody-NKG2D ligand fusion protein results in an enhanced innate and adaptive antitumor response.
    Cho HM; Rosenblatt JD; Tolba K; Shin SJ; Shin DS; Calfa C; Zhang Y; Shin SU
    Cancer Res; 2010 Dec; 70(24):10121-30. PubMed ID: 21159634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma.
    Xuan C; Steward KK; Timmerman JM; Morrison SL
    Blood; 2010 Apr; 115(14):2864-71. PubMed ID: 20139095
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An IgG3-IL-2 fusion protein recognizing a murine B cell lymphoma exhibits effective tumor imaging and antitumor activity.
    Penichet ML; Harvill ET; Morrison SL
    J Interferon Cytokine Res; 1998 Aug; 18(8):597-607. PubMed ID: 9726441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted delivery of an antibody-mutant human endostatin fusion protein results in enhanced antitumor efficacy.
    Shin SU; Cho HM; Merchan J; Zhang J; Kovacs K; Jing Y; Ramakrishnan S; Rosenblatt JD
    Mol Cancer Ther; 2011 Apr; 10(4):603-14. PubMed ID: 21393427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A recombinant IgG3-(IL-2) fusion protein for the treatment of human HER2/neu expressing tumors.
    Penichet ML; Dela Cruz JS; Shin SU; Morrison SL
    Hum Antibodies; 2001; 10(1):43-9. PubMed ID: 11455061
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced inhibition of murine tumor and human breast tumor xenografts using targeted delivery of an antibody-endostatin fusion protein.
    Cho HM; Rosenblatt JD; Kang YS; Iruela-Arispe ML; Morrison SL; Penichet ML; Kwon YG; Kim TW; Webster KA; Nechustan H; Shin SU
    Mol Cancer Ther; 2005 Jun; 4(6):956-67. PubMed ID: 15956253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with novel combinations of anti-HER2/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2/neu expressing tumors.
    Helguera G; Dela Cruz JS; Lowe C; Ng PP; Trinh R; Morrison SL; Penichet ML
    Vaccine; 2006 Jan; 24(3):304-16. PubMed ID: 16125282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein.
    Dela Cruz JS; Morrison SL; Penichet ML
    Vaccine; 2005 Sep; 23(39):4793-803. PubMed ID: 15967544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-CD20-interferon-β fusion protein therapy of murine B-cell lymphomas.
    Trinh KR; Vasuthasawat A; Steward KK; Yamada RE; Timmerman JM; Morrison SL
    J Immunother; 2013 Jun; 36(5):305-18. PubMed ID: 23719241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A single-chain IL-12 IgG3 antibody fusion protein retains antibody specificity and IL-12 bioactivity and demonstrates antitumor activity.
    Peng LS; Penichet ML; Morrison SL
    J Immunol; 1999 Jul; 163(1):250-8. PubMed ID: 10384123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism of antitumor activity of a single-chain interleukin-12 IgG3 antibody fusion protein (mscIL-12.her2.IgG3).
    Peng LS; Penichet ML; Dela Cruz JS; Sampogna SL; Morrison SL
    J Interferon Cytokine Res; 2001 Sep; 21(9):709-20. PubMed ID: 11576465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymalic acid nanobioconjugate for simultaneous immunostimulation and inhibition of tumor growth in HER2/neu-positive breast cancer.
    Ding H; Helguera G; Rodríguez JA; Markman J; Luria-Pérez R; Gangalum P; Portilla-Arias J; Inoue S; Daniels-Wells TR; Black K; Holler E; Penichet ML; Ljubimova JY
    J Control Release; 2013 Nov; 171(3):322-9. PubMed ID: 23770212
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
    Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
    Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-HER2/neu IgG3-(IL-2) and anti-HER2/neu IgG3-(GM-CSF) promote HER2/neu processing and presentation by dendritic cells: implications in immunotherapy and vaccination strategies.
    Dela Cruz JS; Trinh KR; Chen HW; Ribas A; Morrison SL; Penichet ML
    Mol Immunol; 2006 Feb; 43(6):667-76. PubMed ID: 15908002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased survival of human breast cancer cells expressing HER2/neu on in vitro incubation with an anti-HER2/neu antibody fused to C5a or C5a desArg.
    Fuenmayor J; Perez-Vazquez K; Perez-Witzke D; Penichet ML; Montano RF
    Mol Cancer Ther; 2010 Aug; 9(8):2175-85. PubMed ID: 20682652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice.
    Dela Cruz JS; Lau SY; Ramirez EM; De Giovanni C; Forni G; Morrison SL; Penichet ML
    Vaccine; 2003 Mar; 21(13-14):1317-26. PubMed ID: 12615426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas.
    Rossi EA; Goldenberg DM; Cardillo TM; Stein R; Chang CH
    Blood; 2009 Oct; 114(18):3864-71. PubMed ID: 19710501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.